Analyst Research

Report Title Price
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Rexahn Pharmaceuticals Inc Appoints Peter D. Suzdak As Chief Executive Officer


Tuesday, 22 Jan 2013 08:00am EST 

Rexahn Pharmaceuticals Inc announced that it has appointed Dr. Peter D. Suzdak as its new Chief Executive Officer (CEO). He succeeds Dr. Chang Ahn, who will move into the role of Chief Scientist and will remain as Chairman of the Board. 

Company Quote

0.81
-0.0239 -2.87%
11 Jul 2014